PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis

Covid19 Clinical Trial

Official title:

PsoVac: A Psoriatic Patient-based Survey on the Understanding of the Use of Vaccines While on Biologics During the Covid-19 Pandemic

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04513847
• Other study ID #: Pso-Vac
• Status: Completed
• Start date: August 13, 2020
• Est. completion date: October 6, 2020

Study information

• Verified date: October 2020
• Source: Dermatrials Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To determine if there is a need for further education on vaccines with psoriasis patients who are on a biologic. In regards to the COVID-19, it is important that psoriasis patients - whether on a biologic or not - understand whether they can have certain vaccines. That will depend on the type of vaccine that becomes available.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 661
• Est. completion date: October 6, 2020
• Est. primary completion date: September 13, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• psoriasis patient

Exclusion Criteria:

• no exclusions

Related Conditions & MeSH terms

• Covid19
• Psoriasis

Locations

Country	Name	City	State
Canada	Dermatrials Research	Hamilton	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Dermatrials Research

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients not understanding the interaction of vaccines and their biologic, assessed with voluntary survey.	Assessment is based upon survey responses. By answering multiple questions we will determine if more education is needed based on the answers.	Data will be collected over a span of 3 months